Optimizing Medical Management of Relapsed or Refractory Follicular and Marginal Zone Lymphomas: A Critical Look at the Evidence for Managed Care Pharmacists

Description:,Patients with indolent lymphomas such as follicular and marginal zone lymphomas require long-term treatment with multiple therapies as these diseases are not curable. New agents and approved combinations for the treatment of indolent lymphomas have the potential to improve the quality of life for patients, help them achieve longer periods of remission, and mitigate the financial burden. As the cost of care and treatment burden is closely related to what line of therapy patients receive, pharmacists practicing on oncology care teams must be familiar with preferred and recommended therapy regimens. This activity will focus on the pharmacist’s role in the treatment and management of follicular lymphoma and marginal zone lymphoma and considerations for optimizing resource utilization for these therapies.,Pharmacist Educational Objectives,At the completion of this activity, participants will be able to:,• Examine recent updates to current guidelines around the treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL), including the addition of CD-19-directed therapies and bispecific antibodies.,• Identify the safety and efficacy of newer therapies alongside current standard-of-care oral oncolytic to manage therapies for patients with FL and MZL.,• Explain costs associated with the treatment of indolent lymphomas and considerations for the development of utilization management tools.